clinical trial · NCT05644717
Effect of Erugliflozin On Liver Fat, Liver Fibrosis and Glycemic Control in Type II DM Patients With NASH/NAFLD
Getz Pharma·phase4·recruiting·n = 164
Liver FatLiver FibrosisGlycemic ControlBody Weight ChangesWaist CircumferenceToleranceErtugliflozin 5 mg, 15mg
brief summary
Open-label, prospective, single-arm, multicenter study to determine effects of Ertugliflozin on liver fat, liver fibrosis \& glycemic control in subjects with Type 2 Diabetes Mellitus (T2DM) with Non-Alcoholic Fatty Liver Disease (NAFLD)/Non-Alcoholic Steatohepatitis (NASH)
started
Mar 1, 2023
primary completion
Nov 1, 2025
completion
Dec 1, 2025
last updated
Mar 21, 2025
official title
Effects of Ertugliflozin on Liver Fat, Liver Fibrosis & Glycemic Control in Subjects With Type 2 Diabetes Mellitus (T2DM) & Non-Alcoholic Fatty Liver Disease /Non-Alcoholic Steatohepatitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol